Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Jun 5.
doi: 10.1007/s11255-025-04596-x. Online ahead of print.

Reassessing finerenone's role in IgA nephropathy: methodological and clinical considerations

Muhammad Naveed  1 , Uzair Ahmed  2 , Syyeda Nargis  3
Affiliations
Comment

Reassessing finerenone's role in IgA nephropathy: methodological and clinical considerations

Muhammad Naveed et al. Int Urol Nephrol. .

Abstract

This letter addresses the study "Effectiveness and Safety of Finerenone in the Treatment of IgA Nephropathy Patients" by Qingqing Gao, which investigates finerenone as adjunct therapy in IgA nephropathy. While the study offers promising insights, key methodological limitations-including lack of randomization, blinding, and small sample size-raise concerns regarding selection bias and external validity. Additionally, the omission of important clinical parameters such as blood pressure and inflammatory markers limits the scope of safety monitoring. The letter emphasizes the need for larger, multicenter, randomized controlled trials with improved monitoring strategies, including MEST-C scoring, to enhance diagnostic accuracy and outcome interpretation. Despite the study's strengths in reporting UACR reduction and stable eGFR, a more rigorous research design is essential to fully evaluate finerenone's long-term efficacy and safety in this patient population.

Keywords: Drug safety; Finerenone; IgA nephropathy; MEST-C score.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no competing interests.

Comment on

Similar articles

See all similar articles

References

    1. Gao Q, Lin H, Zhao Z, Peng S, Wu Q, Dong X et al (2025) Effectiveness and safety of finerenone in the treatment of IgA Nephrology patients: a retrospective, real-world study. Int Urol Nephrol. https://doi.org/10.1007/s11255-025-04512-3 - DOI - PubMed - PMC
    1. Siemonsma PC, Walker MF (1997) Practical guidelines for independent assessment in randomized controlled trials (RCTs) of rehabilitation. Clin Rehabil. https://doi.org/10.1177/026921559701100402 - DOI - PubMed
    1. Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Anker SD, et al. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens [Internet]. 2023 Feb 1 [cited 2025 May 3];41(2):295–302. https://journals.lww.com/jhypertension/fulltext/2023/02000/effect_of_fin...
    1. Saleem N, Nasir H, Anwar F, Aziz M, Khurshid K, Bashir S et al (2024) To evaluate the utility of Oxford classification in predicting renal outcome in IgA nephropathy patients. Int Urol Nephrol. https://doi.org/10.1007/s11255-023-03685-z - DOI - PubMed
    1. Das MK (2022) Multicenter studies: relevance, design and implementation. Indian Pediatr. https://doi.org/10.1007/s13312-022-2561-y - DOI - PubMed - PMC

LinkOut - more resources